THE cold weather can trigger a range of symptoms, with the most common being shivering. But if certain symptoms seem out of ...

Updating peak systemic mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT® (avapritin ...

RBC Capital analyst Gregory Renza lowered the firm’s price target on Jasper Therapeutics (JSPR) to $48 from $68 and keeps an Outperform rating ...

Welcome to the Novartis presentation at the 43rd JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst with JPMorgan. It's my great pleasure to introduce Vas Narasimhan, the CEO ...

Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25Kymera plans to initiate a KT-621 Phase 1b trial in atopic ...

Image Source: Zacks Investment Research Blueprint is conducting an early-stage study of BLU-808 to assess its unique potency ...

Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million-- --2025 Global ARIKAYCE Revenues Expected to be Between $405 Million ...

Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...

P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, ...

The Montair LC tablet is an antiallergic tablet that relieves sneezing, itching, watery eyes, stuffy nose, and runny nose ...

After developing chronic pain, I started looking into what scientists do — and still don’t — understand about the disease.

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...